PT3038609T - Modificadores de resposta de células t citotóxicas - Google Patents

Modificadores de resposta de células t citotóxicas

Info

Publication number
PT3038609T
PT3038609T PT14761596T PT14761596T PT3038609T PT 3038609 T PT3038609 T PT 3038609T PT 14761596 T PT14761596 T PT 14761596T PT 14761596 T PT14761596 T PT 14761596T PT 3038609 T PT3038609 T PT 3038609T
Authority
PT
Portugal
Prior art keywords
cytotoxic
cell response
response modifiers
modifiers
cell
Prior art date
Application number
PT14761596T
Other languages
English (en)
Original Assignee
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforsch filed Critical Deutsches Krebsforsch
Publication of PT3038609T publication Critical patent/PT3038609T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
PT14761596T 2013-08-27 2014-08-27 Modificadores de resposta de células t citotóxicas PT3038609T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361870421P 2013-08-27 2013-08-27

Publications (1)

Publication Number Publication Date
PT3038609T true PT3038609T (pt) 2021-10-01

Family

ID=51494273

Family Applications (1)

Application Number Title Priority Date Filing Date
PT14761596T PT3038609T (pt) 2013-08-27 2014-08-27 Modificadores de resposta de células t citotóxicas

Country Status (9)

Country Link
US (3) US9994854B2 (pt)
EP (1) EP3038609B1 (pt)
JP (1) JP2016535060A (pt)
CN (1) CN105517542B9 (pt)
CA (1) CA2918568A1 (pt)
DK (1) DK3038609T3 (pt)
ES (1) ES2891081T3 (pt)
PT (1) PT3038609T (pt)
WO (1) WO2015028515A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3538549A1 (en) * 2016-11-10 2019-09-18 iOmx Therapeutics AG Or10h1 antigen binding proteins and uses thereof
EP3321280B8 (en) * 2016-11-10 2021-03-10 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Immune modulators for reducing immune-resistance in melanoma and other proliferative diseases
JP2021521248A (ja) * 2018-04-16 2021-08-26 ラ ホヤ インスティテュート フォア アラージー アンド イムノロジー 嗅覚受容体活性を標的とすることによる免疫応答のモジュレート
JP2022526340A (ja) * 2019-03-25 2022-05-24 マックス-デルブリュック-ツェントルム フューア モレキュラーレ メディツィン イン デア ヘルムホルツ-ゲマインシャフト Ebag9を阻害することによる細胞溶解性t細胞の活性の増強
WO2021024742A1 (ja) * 2019-08-06 2021-02-11 国立大学法人筑波大学 細胞傷害アッセイ方法
KR102631623B1 (ko) * 2021-04-16 2024-02-02 경북대학교 산학협력단 젖산에 의한 종양 관련 대식세포의 m2형 분화 및 종양 성장의 억제를 위한 후각수용체의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0507672D0 (en) * 2005-04-15 2005-05-25 Barnaba Vincenzo Adjuvant
DE102006008074B4 (de) * 2006-02-22 2013-08-14 RUHR-UNIVERSITäT BOCHUM Behandlung von Krebs mit Geruchsrezeptor-Liganden
EP1881080A1 (en) * 2006-07-18 2008-01-23 Institut Gustave Roussy Toll like receptor 4 dysfunction and the biological applications thereof
WO2008022104A1 (en) * 2006-08-15 2008-02-21 Hutchison Medipharma Enterprises Limited Costunolide derivatives
US9764012B2 (en) * 2009-04-01 2017-09-19 University Of Miami Vaccine compositions and methods of use thereof
US8673578B2 (en) * 2009-10-27 2014-03-18 Deutsches Institut für Ernahrungsforschung Potsdam-Rehbrücke Methods of identifying antagonists of the hTAS2R46 bitter taste receptor
US9044492B2 (en) * 2011-02-04 2015-06-02 Cellectis Sa Method for modulating the efficiency of double-strand break-induced mutagenesis

Also Published As

Publication number Publication date
EP3038609B1 (en) 2021-07-28
DK3038609T3 (da) 2021-09-13
JP2016535060A (ja) 2016-11-10
US11802285B2 (en) 2023-10-31
CA2918568A1 (en) 2015-03-05
US20200002706A1 (en) 2020-01-02
CN105517542A (zh) 2016-04-20
EP3038609A1 (en) 2016-07-06
US20180298388A1 (en) 2018-10-18
US9994854B2 (en) 2018-06-12
WO2015028515A1 (en) 2015-03-05
CN105517542B (zh) 2021-12-07
HK1225614A1 (en) 2017-09-15
US20160201066A1 (en) 2016-07-14
ES2891081T3 (es) 2022-01-26
CN105517542B9 (zh) 2022-01-11

Similar Documents

Publication Publication Date Title
IL245572A0 (en) cell
GB201306312D0 (en) Tablet case
GB201413149D0 (en) No details
AU356417S (en) Battery
AU355178S (en) Earring
AU353527S (en) Earring
GB201518344D0 (en) No details present
GB201506699D0 (en) No details
GB201421649D0 (en) No details
GB201418212D0 (en) No details
GB201410903D0 (en) No details
GB201416327D0 (en) No details
GB201421548D0 (en) No details
GB201408089D0 (en) No details
GB201418129D0 (en) No details
GB201418214D0 (en) No details
GB201310031D0 (en) Cell
GB201312000D0 (en) Alloy
PT3038609T (pt) Modificadores de resposta de células t citotóxicas
GB201312332D0 (en) Cell locations
IL241350A0 (en) Subprevir tablets
GB201407200D0 (en) No details
GB201417843D0 (en) No details
GB201420520D0 (en) No details
SMT201700220T1 (it) Compressa contenente 5-idrossi-1h-imidazol-4-carbossammide